

28 June 2021

Company Announcements Office
Australian Securities Exchange

Nanosonics to launch new infection prevention digital product platform, Nanosonics AuditPro, for traceability, reporting and compliance

- **New digital product platform, Nanosonics AuditPro™, to be launched at the Association for Professionals in Infection Control (APIC) on 28 June 2021.**
- **Nanosonics AuditPro, developed to provide a new digital workflow compliance management system with potential applicability across a range of medical instruments.**
- **New revenue stream associated with mobile scanning device and subscription-based software that provides real time access for customers to necessary infection prevention compliance data.**
- **First application focuses on a solution for the ultrasound market, with potential for the new product to be coupled with every ultrasound console at point of care.**

Nanosonics today announced it will launch a new digital product platform offering digital traceability, reporting and compliance, Nanosonics AuditPro™, at the Association for Professionals in Infection Control (APIC) conference in the United States on 28 June 2021. A national rollout across the United States is anticipated to commence from July 2021.

Nanosonics AuditPro represents an opportunity to improve and standardise infection control compliance across a broad range of medical instruments to support the management of healthcare acquired infection (HAI) risks, ultimately supporting best patient care.

“As previously reported, we have a number of active programs across five core areas of R&D interest in the infection prevention landscape. These areas consist of instrument cleaning, instrument disinfection, storage solutions, environmental decontamination and compliance & traceability. Nanosonics AuditPro is one of the new products previously foreshadowed and represents the first product to be brought to market from our compliance and traceability R&D program. This new product represents the first IoT (Internet of Things) offering from Nanosonics in a new and discrete digital product line. Further updates in respect of our broader R&D program will be provided throughout FY22,” said Michael Kavanagh, Nanosonics’ Chief Executive Officer and President.

“Nanosonics AuditPro is the result of a number of years in research and development and opens up a significant opportunity to market a unique solution that provides a digital workflow compliance management system for tracking various instruments used in medical procedures. This is an important aspect of infection prevention to ensure medical instruments have been appropriately disinfected in accordance with relevant standards.

“The new Nanosonics AuditPro digital solution is comprised of a mobile scanning device coupled with a subscription to a browser-based application for users. It delivers real time access to a broad range of compliance and traceability data for customers as well as a new revenue stream for Nanosonics.

“The first application focuses on ultrasound procedures, with the new handheld device designed to be coupled with every ultrasound console at point of care.

“Every year over 650 million ultrasound procedures are conducted globally. These procedures are conducted across many different departments in hospitals, affiliated clinics and private physician clinics. As a reusable medical device, ultrasound probes need to be appropriately disinfected in accordance with the relevant standards to reduce the risk of patient cross-contamination. These standards require clinicians to be able to determine if a probe needs to be Low Level Disinfected (LLD), High Level Disinfected (HLD) or Sterilised based on the procedure the probe will be used for. With built in education as part of the Nanosonics AuditPro workflow, clinicians can qualify every procedure against the disinfection requirements, therefore standardising the infection prevention decision every time.

“With the introduction of Nanosonics AuditPro, together with our existing trophon technology and other product developments currently progressing through our R&D program, Nanosonics continues to focus on the delivery of a portfolio of innovative infection prevention solutions to market,” said Michael Kavanagh, Nanosonics’ Chief Executive Officer and President.

Michael Kavanagh
CEO / President

This announcement has been authorised by the Board of Directors of Nanosonics Limited.

For more information, please contact:

Michael Kavanagh, CEO / President or McGregor Grant, CFO, on (02) 8063 1600.